Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in

Status Completed

Clinical Trial Summary

Ten subjects will be enrolled in the study. Each subject will have their left and right forehead randomly assigned to receive 4 units of PrabotulinumtoxinA-xvfs or OnabotulinumtoxinA. Subjects will be reassessed at 2 weeks for evaluation of rhytide diminution around each injection point to assess relative diffusion of each drug in the forehead.

Clinical Trial Description

This is a prospective, single-center, blinded, randomized, split-face study to investigate the area of spread or diffusion of onabotulinumtoxinA and prabotulinumtoxinA at the same dilution and dose in the treatment of forehead lines in adult subjects. Ten adult subjects, 18 years or older, with moderate-to-severe dynamic and none-to-minimal static forehead lines will be enrolled. Upon enrollment and after a thorough review of the inclusion and exclusion criteria as well as obtaining written and informed consent, each subject will be randomized to have either their right forehead or left forehead treated with 4 units or 0.1 cc of prabotulinumtoxinA 2.5 cm above the orbital rim. As a control, the contralateral forehead half will receive 4 units or 0.1 cc of onabotulinumtoxinA at the same dilution. If applicable, a urine pregnancy test will be obtained prior to treatment. Subjects may be treated on the same day that they are screened and provide informed consent. Given the small volume of injection, tuberculin hubless syringes will be used to ensure accuracy of specific injection volumes. Injections will be delivered intramuscularly with the needle at a 90-degree angle or perpendicular to the skin surface. The left and right-side assignment will be determined based on the treating physician's selection of a sealed envelope using random numbers on the treatment day. Following initial treatment, the subjects will be re-evaluated at a Day 14. Surface area of rhytide reduction will be measured in centimeters squared (incorporating length and width measurements) two-weeks post-injection to assess differences, if any, in rhytid reduction on each side of the forehead by a blinded investigator. The field of rhytid reduction (visual absence of horizontal forehead rhytids) will be measured while the frontalis fully contracted. Any adverse events will be recorded at the 2-week follow up. After the Day 14 assessment subjects will exit the study after which the investigator will assess the patient for any asymmetry and if the investigator deems it appropriate and the subject desires it, a touch up correction will be performed. Subjects will be photographed at baseline and two weeks after treatment using Visia and 2D photography. Photos will be taken before and after marking the points of injection. Moreover, photos will be taken both with the frontalis muscle fully relaxed and fully contracted. ;

Study Design

Related Conditions & MeSH terms

Rhytides

Clinical Trial Details

NCT number	NCT05807412
Study type	Interventional
Source	Lupo Center for Aesthetic and General Dermatology
Contact
Status	Completed
Phase	Early Phase 1
Start date	May 1, 2023
Completion date	February 26, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT00495443` - Enhanced Safety Aesthetic Laser System	N/A
Completed	`NCT04586816` - Randomized, Double-Blind Evaluation of Maple Leaf Extract (Maplifa) for Photoaging	N/A
Completed	`NCT02954315` - The Effect of Almonds on Skin Lipids and Wrinkles	N/A
Completed	`NCT01460927` - TriActive+ Radiofrequency (RF) for Non-invasive Treatment of Wrinkles & Rhytides	N/A
Withdrawn	`NCT04994990` - Effective OnabotulinumtoxinA Dose Response Study for Upper Facial Wrinkles	N/A
Completed	`NCT01859611` - TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides	N/A
Completed	`NCT03776461` - Fractional Radiofrequency for the Treatment and Reduction of Facial Wrinkles	N/A
Completed	`NCT05514834` - BCT-HA Kit for Dehydrated and Wrinkled Skin	Early Phase 1
Enrolling by invitation	`NCT06104514` - Safety and Efficacy of SofWave Treatment to Lift the Upper Lip and Improve the Peri-Oral Rhytids	N/A
Completed	`NCT03286283` - The Use of J-Plasma® for Dermal Resurfacing	N/A
Completed	`NCT05041465` - The Cosmetic Effect of Mineral Clay Masks	N/A
Completed	`NCT06421207` - Open Label Study Exploring Tissue Histopathology After Ellacor® Procedure in an Abdominoplasty Model.	N/A
Completed	`NCT04185909` - Renuvion Dermal System for Dermal Resurfacing	N/A
Completed	`NCT03831477` - Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Facial Wrinkles	N/A
Completed	`NCT05517538` - Split-face Study: Cosmetic Botulinum Toxin Type A Injection Under Electromyography-guidance Versus Conventional Palpation Technique	N/A
Active, not recruiting	`NCT04162496` - Restylane Refyne for Correction of Horizontal Neck Rhytides	N/A
Withdrawn	`NCT02659124` - Comparison of AmnioFix Laser and Standard of Care Treatment	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms